Development of Magnetic Resonance (MR) Simulation for Treatment Planning

This study has been completed.
Information provided by (Responsible Party):
AHS Cancer Control Alberta Identifier:
First received: April 11, 2006
Last updated: January 5, 2012
Last verified: January 2012

Retrospectively have access to MR images of patients to develop software that:

  1. segment images
  2. convert MR values to electron density and then
  3. entered into a dose calculation system

The project involves software development of data that is already available. No intervention is made at this point.


Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Development of MR Simulation for Treatment Planning

Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 10
Study Start Date: September 2005
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adult patient with conform histological diagnosis of glioblastoma multiforme signed the consent forms and were willing to go for curative radiation treatment with temozolomide


Inclusion Criteria:

  • Subject 18 years of age and older
  Contacts and Locations
Please refer to this study by its identifier: NCT00314496

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Principal Investigator: Gino Fallone, PhD AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta Identifier: NCT00314496     History of Changes
Other Study ID Numbers: EX-0004
Study First Received: April 11, 2006
Last Updated: January 5, 2012
Health Authority: Canada: Health Canada processed this record on April 15, 2014